Compare Stocks: EPRX, TRLV, ANAB, and SEPN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$53.36	$57.73	$11.40 ▼ $72.36	$1.58B	0.72	780,174 shs	451,354 shs
EPRX Eupraxia Pharmaceuticals	$6.40	$6.47	$5.04 ▼ $9.32	$416.13M	1.08	369,505 shs	457,159 shs
SEPN Septerna	$34.45	$33.58	$10.62 ▼ $38.04	$1.55B	2.29	401,858 shs	241,094 shs
TRLV Trulieve Cannabis	$8.62 -0.4%	$0.00	$4.19 ▼ $13.28	$1.66B	N/A	641,277 shs	711,430 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	0.00%	-1.46%	-15.86%	-20.07%	+116.12%
EPRX Eupraxia Pharmaceuticals	0.00%	+10.15%	-4.33%	-18.88%	+20.66%
SEPN Septerna	0.00%	+4.08%	+1.32%	+45.91%	+182.15%
TRLV Trulieve Cannabis	0.00%	+2.95%	-11.39%	+861,899,900.00%	+861,899,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$53.36	$57.73	$11.40 ▼ $72.36	$1.58B	0.72	780,174 shs	451,354 shs
EPRX Eupraxia Pharmaceuticals	$6.40	$6.47	$5.04 ▼ $9.32	$416.13M	1.08	369,505 shs	457,159 shs
SEPN Septerna	$34.45	$33.58	$10.62 ▼ $38.04	$1.55B	2.29	401,858 shs	241,094 shs
TRLV Trulieve Cannabis	$8.62 -0.4%	$0.00	$4.19 ▼ $13.28	$1.66B	N/A	641,277 shs	711,430 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	0.00%	-1.46%	-15.86%	-20.07%	+116.12%
EPRX Eupraxia Pharmaceuticals	0.00%	+10.15%	-4.33%	-18.88%	+20.66%
SEPN Septerna	0.00%	+4.08%	+1.32%	+45.91%	+182.15%
TRLV Trulieve Cannabis	0.00%	+2.95%	-11.39%	+861,899,900.00%	+861,899,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANAB AnaptysBio	2.67	Moderate Buy	$82.00	53.67% Upside
EPRX Eupraxia Pharmaceuticals	2.89	Moderate Buy	$18.00	181.25% Upside
SEPN Septerna	2.82	Moderate Buy	$45.89	33.20% Upside
TRLV Trulieve Cannabis	2.00	Hold	$15.00	74.03% Upside

Current Analyst Ratings Breakdown

Latest EPRX, TRLV, ANAB, and SEPN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/20/2026	TRLV Trulieve Cannabis	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$15.00
7/17/2026	EPRX Eupraxia Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	SEPN Septerna	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	EPRX Eupraxia Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
7/1/2026	SEPN Septerna	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$52.00 ➝ $45.00
7/1/2026	SEPN Septerna	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$35.00 ➝ $43.00
7/1/2026	SEPN Septerna	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00
6/25/2026	EPRX Eupraxia Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$17.00
6/18/2026	TRLV Trulieve Cannabis	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
6/16/2026	TRLV Trulieve Cannabis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (D-)
6/11/2026	SEPN Septerna	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$52.00

(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANAB AnaptysBio	$234.60M	6.73	N/A	N/A	$1.34 per share	39.82
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	$1.41 per share	N/A
SEPN Septerna	$45.95M	33.80	N/A	N/A	$8.53 per share	4.04
TRLV Trulieve Cannabis	$1.17B	1.42	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANAB AnaptysBio	-$13.23M	-$1.08	N/A	16.42	N/A	-11.53%	N/A	-7.75%	8/5/2026 (Estimated)
EPRX Eupraxia Pharmaceuticals	-$38.58M	-$1.05	N/A	N/A	N/A	N/A	-87.56%	-51.20%	8/11/2026 (Estimated)
SEPN Septerna	-$48.88M	-$0.81	N/A	N/A	N/A	-49.88%	-12.72%	-8.87%	8/10/2026 (Estimated)
TRLV Trulieve Cannabis	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest EPRX, TRLV, ANAB, and SEPN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	EPRX Eupraxia Pharmaceuticals	-$0.25	N/A	N/A	N/A	N/A	N/A
8/10/2026	Q2 2026	SEPN Septerna	-$0.4260	N/A	N/A	N/A	$19.22 million	N/A
8/5/2026	Q2 2026	ANAB AnaptysBio	-$0.1252	N/A	N/A	N/A	$17.33 million	N/A
5/12/2026	Q1 2026	ANAB AnaptysBio	-$0.6436	-$1.84	-$1.1965	-$1.84	$18.86 million	$25.56 million
5/12/2026	Q1 2026	EPRX Eupraxia Pharmaceuticals	-$0.22	-$0.23	-$0.01	-$0.23	N/A	N/A
5/11/2026	Q1 2026	SEPN Septerna	-$0.4167	-$0.19	+$0.2267	-$0.19	$16.98 million	$26.52 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SEPN Septerna	N/A	N/A	N/A	N/A	N/A
TRLV Trulieve Cannabis	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANAB AnaptysBio	N/A	7.58	7.58
EPRX Eupraxia Pharmaceuticals	0.02	19.31	19.31
SEPN Septerna	N/A	4.71	4.71
TRLV Trulieve Cannabis	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANAB AnaptysBio	N/A
EPRX Eupraxia Pharmaceuticals	N/A
SEPN Septerna	N/A
TRLV Trulieve Cannabis	N/A

Insider Ownership

Company	Insider Ownership
ANAB AnaptysBio	31.50%
EPRX Eupraxia Pharmaceuticals	N/A
SEPN Septerna	5.80%
TRLV Trulieve Cannabis	3.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANAB AnaptysBio	100	29.61 million	20.28 million	Optionable
EPRX Eupraxia Pharmaceuticals	29	65.02 million	N/A	N/A
SEPN Septerna	N/A	45.08 million	42.46 million	N/A
TRLV Trulieve Cannabis	9,000	192.31 million	N/A	N/A

EPRX, TRLV, ANAB, and SEPN Headlines

Recent News About These Companies

Trulieve Cannabis Corp. (NYSE:TRLV) Sees Large Growth in Short Interest

July 28, 2026 | marketbeat.com

Cantor Fitzgerald Begins Coverage on Trulieve Cannabis (NYSE:TRLV)

July 20, 2026 | marketbeat.com

Trulieve to Open Medical Cannabis Dispensary in Marco Island, Florida

July 16, 2026 | prnewswire.com

Trulieve Cannabis Corp. (NYSE:TRLV) Sees Significant Growth in Short Interest

July 14, 2026 | marketbeat.com

Why Is Trulieve (NYSE:TRLV) Expanding Its NYSE Presence?

July 13, 2026 | kalkinemedia.comK

Two marijuana MSOs named among ‘America’s Best Companies’

July 10, 2026 | mjbizdaily.comM

Trulieve Cannabis Corp. to Hold Second Quarter 2026 Results Conference Call on August 7, 2026

July 10, 2026 | prnewswire.com

Trulieve Named to TIME's America's Best Companies 2026 List

July 10, 2026 | prnewswire.com

Better Cannabis Growth Stock: Trulieve or Vireo Growth

July 10, 2026 | fool.com

Trulieve (NYSE:TRLV) NYSE Listing Redefines Cannabis Market Access

July 8, 2026 | kalkinemedia.comK

Trulieve targets September opening for 3 Texas MMJ stores

July 7, 2026 | mjbizdaily.comM

Trulieve Cannabis (NYSE:TRLV) Opens a New Market Era

July 7, 2026 | kalkinemedia.comK

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

July 7, 2026 | money.usnews.com

MSOS Hits a 2026 High as Cannabis Stocks Brace for DEA's July 15 Rescheduling Deadline

July 3, 2026 | investorideas.comI

Trulieve Commemorates Georgia Medical Cannabis Launch with First Sale

July 1, 2026 | prnewswire.com

Trulieve CEO Sells $1.2 Million in Stock as Shares Jump 148% in One Year

June 27, 2026 | fool.com

Trulieve Cannabis (NYSE:TRLV) CEO Sells 136,811 Shares

June 27, 2026 | insidertrades.com

Trulieve Announces Planned Termination of Executive Automatic Securities Disposition Plan

June 26, 2026 | prnewswire.com

TRLV PE / PEG Ratio

June 26, 2026 | seekingalpha.com

Insider Selling: Trulieve Cannabis (NYSE:TRLV) CEO Sells $2,451,000.00 in Stock

June 26, 2026 | insidertrades.com

TRLV Trulieve Cannabis Corp.

June 24, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPRX, TRLV, ANAB, and SEPN Company Descriptions

AnaptysBio NASDAQ:ANAB

$53.36 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$53.24 -0.12 (-0.22%)

As of 07/31/2026 07:34 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Eupraxia Pharmaceuticals NASDAQ:EPRX

$6.40 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$6.40 0.00 (0.00%)

As of 07/31/2026 07:34 PM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Septerna NASDAQ:SEPN

$34.45 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$34.45 0.00 (0.00%)

As of 07/31/2026 07:34 PM Eastern

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body. Due to their significant role in human diseases, GPCRs have been the most productive target class in drug discovery history, accounting for approximately one-third of all U.S. Food and Drug Administration (FDA) approved drugs, representing approximately 500 products with combined global revenue of approximately $125 billion in 2023. Despite the pharmacological and commercial success of GPCR-targeted agents, about 75% of potential GPCR therapeutic targets remain undrugged and, for certain validated GPCRs, novel binding pockets may exist that could offer enhanced therapeutic benefits. Each step in GPCR activation involves subtle conformational changes that have been historically challenging to reproduce outside of a cell. The inability to isolate GPCR proteins in their native functional form outside of a cellular context has prevented scientists from leveraging some of the state-of-the-art technologies that have revolutionized drug discovery in other major target classes over the past decade. This complex challenge has limited GPCR drug discovery, particularly the development of novel oral small molecules, such as agonists (which activate GPCR signaling) for peptide GPCRs and allosteric modulators (which either increase or decrease the degree of GPCR activation by endogenous ligands). Our proprietary Native Complex Platform™ replicates the natural structure, function, and dynamics of GPCRs outside of cells at an industrial scale for, as we believe it, the first time. Our foundational technologies enable us to isolate, purify, and reconstitute full-length, properly folded GPCR proteins within ternary complexes with ligands and transducer proteins in a lipid bilayer that mimics the cell membrane. We then apply state-of-the-art discovery tools and technologies to these defined and tunable protein complexes to structurally design, screen for, and optimize potential product candidates. Leveraging our platform, we conduct GPCR oral small molecule drug discovery using an industrialized and iterative structure-based drug design approach for a diverse collection of GPCR targets. Our Native Complex PlatformTM is designed to enable us to target specific GPCRs, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists (which inhibit GPCR signaling), and allosteric modulators, to affect GPCR signaling in different ways to achieve desired therapeutic effects. We are advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. Our wholly-owned pipeline, is focused initially on three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. We intend to evaluate opportunities in other major therapeutic areas, such as neurology, women's health, cardiovascular, and respiratory disease. --- Leveraging our team, scientific and technical advisors, and our proprietary Native Complex Platform™, we aim to be a leader in the development of oral GPCR-targeted medicines for patients with significant unmet needs. We were incorporated under the laws of the State of Delaware in December 2019 under the name GPCR NewCo, Inc. and changed our name to Septerna, Inc. in June 2021. Our principal executive offices are located at 250 East Grand Avenue, South San Francisco, California.

Trulieve Cannabis NYSE:TRLV

$8.62 -0.03 (-0.36%)

Closing price 07/31/2026 03:59 PM Eastern

Extended Trading

$8.55 -0.07 (-0.80%)

As of 07/31/2026 07:56 PM Eastern

Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, California, Massachusetts, Connecticut, Pennsylvania, and West Virginia, as well as directly to patients through home delivery. It produces approximately 550 stock keeping units, including flower, edibles, vaporizer cartridges, concentrates, topicals, capsules, tinctures, dissolvable powders, and nasal sprays. As of May 5, 2021, the company operated through 87 dispensaries in the United States. The company is headquartered in Quincy, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EPRX, TRLV, ANAB, and SEPN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EPRX, TRLV, ANAB, and SEPN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EPRX, TRLV, ANAB, and SEPN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPRX, TRLV, ANAB, and SEPN Company Descriptions

AnaptysBio NASDAQ:ANAB

Eupraxia Pharmaceuticals NASDAQ:EPRX

Septerna NASDAQ:SEPN

Trulieve Cannabis NYSE:TRLV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EPRX, TRLV, ANAB, and SEPN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EPRX, TRLV, ANAB, and SEPN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EPRX, TRLV, ANAB, and SEPN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPRX, TRLV, ANAB, and SEPN Company Descriptions

AnaptysBio NASDAQ:ANAB

Eupraxia Pharmaceuticals NASDAQ:EPRX

Septerna NASDAQ:SEPN

Trulieve Cannabis NYSE:TRLV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools